Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P20226 (
TATA-binding protein
)
1,297
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Regulation of transcription by RNA polymerase II in eukaryotic cells requires both basal and accessory factors, which interact through specific protein-DNA or protein-protein interactions. The
high mobility group 1 protein
(
HMG1
) was previously demonstrated to be a nonhistone chromatin-associated protein, which selectively recognizes cruciform DNA rather than a specific primary sequence element. During our investigations of proteins that interact with TFIID, we found that purified mammalian
HMG1
, as well as recombinant human
HMG1
, can interact with
TATA-binding protein
(
TBP
) in the presence of a TATA box-containing oligonucleotide to form a specific
HMG1
.
TBP
.promoter complex. This complex prevents TFIIB binding to
TBP
and consequently blocks formation of the preinitiation complex. In contrast, TFIIA can compete with
HMG1
for binding to
TBP
. In an in vitro transcription assay reconstituted with highly purified or recombinant general factors,
HMG1
is able to inhibit transcription by RNA polymerase II over 30-fold. As expected, addition of TFIIA can partially reverse this repression in a concentration-dependent manner. These results demonstrate that
HMG1
, a chromatin-associated protein, has the potential to act as a
TBP
-dependent negative transcription factor and may provide an important link between chromatin structure and the modulation of class II gene transcription.
...
PMID:The high mobility group protein HMG1 can reversibly inhibit class II gene transcription by interaction with the TATA-binding protein. 800 19